29/10/2025
We were pleased to join the recent Taiwan conference on The Clinical Application of Liquid Biopsy in Solid Tumors: Now and Future. The conference was hosted by the Taiwan Society of Personalized Medicine, and co-organized by the Taiwan Oncology Society, Taiwan Precision Medicine Society and Taiwan Society of Laboratory Medicine.
Conference participants called for the inclusion of liquid biopsy in Taiwan’s National Health Insurance (NHI) to ensure that cancer patients have faster access to the most appropriate treatment. Karthik GM, Director, Regulatory Affairs, Guardant Health AMEA and Chung-Fan Lee, Head of Commercial for Taiwan, highlighted the importance of liquid biopsies in treatment selection for patients who do not qualify for tissue biopsies. They also spoke about the growing worldwide acceptance and approval of liquid biopsies as standard of care.
The push for NHI inclusion of liquid biopsy testing and matched therapies is gaining momentum among Taiwanese physicians and key opinion leaders. Guardant Health welcomes these developments and remains committed to expanding access to fast, accurate, and comprehensive blood-based genomic profiling for cancer patients in Taiwan.
Read more about the conference: https://news.gbimonthly.com/tw/article/show.php?num=80907&range=news